MIST Milestone Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: MIST
Price (delayed)
$1.8
Market cap
$152.99M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.84
Enterprise value
$166.88M
Relative Growth:
Rel. Growth:
9
Relative Strength:
Rel. Strength:
67
Relative Valuation:
Rel. Valuation:
N/A
Relative Profitability:
Rel. Profitability:
3
Milestone Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of etripamil, a Phase 3 clinical-stage program, for the treatment of cardiovascular indications. Milestone Pharmaceuticals operates in Canada
Highlights
MIST's quick ratio has plunged by 74% YoY but it is up by 8% from the previous quarter
The EPS is up by 18% YoY but it is down by 8% QoQ
The company's equity has shrunk by 190% QoQ and by 155% YoY
The net income fell by 15% YoY and by 7% QoQ
Key stats
What are the main financial stats of MIST
Market
Valuations
Earnings
Shares outstanding
84.99M
Market cap
$152.99M
Enterprise value
$166.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
PEG
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$55.02M
Net income
-$55.53M
EBIT
-$51.82M
EBITDA
-$51.72M
Free cash flow
-$40.42M
Per share
Balance sheet
Liquidity
EPS
-$0.84
EPS diluted
-$0.84
Free cash flow per share
-$0.61
Book value per share
-$0.33
Revenue per share
$0
TBVPS
$0.71
Total assets
$47.42M
Total liabilities
$65.16M
Debt
$56.39M
Equity
-$17.75M
Working capital
$36.89M
Debt to equity
-3.18
Current ratio
4.97
Quick ratio
4.78
Net debt/EBITDA
-0.27
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-83%
Return on equity
-1,671.2%
Return on invested capital
-63.4%
Return on capital employed
-135.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MIST stock price
How has the Milestone Pharmaceuticals stock price performed over time
Intraday
-2.17%
1 week
-2.17%
1 month
-14.69%
1 year
13.21%
YTD
-23.73%
QTD
-10%
Financial performance
How have Milestone Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$55.02M
Net income
-$55.53M
Gross margin
N/A
Net margin
N/A
The net income fell by 15% YoY and by 7% QoQ
The operating income has contracted by 12% YoY and by 6% from the previous quarter
Price vs fundamentals
How does MIST's price correlate with its fundamentals
Growth
What is Milestone Pharmaceuticals's growth rate over time
Valuation
What is Milestone Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 18% YoY but it is down by 8% QoQ
The company's equity has shrunk by 190% QoQ and by 155% YoY
Efficiency
How efficient is Milestone Pharmaceuticals business performance
The ROIC has shrunk by 71% YoY and by 31% QoQ
MIST's ROA is down by 49% YoY and by 24% QoQ
Dividends
What is MIST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MIST.
Financial health
How did Milestone Pharmaceuticals financials performed over time
The total assets is 27% smaller than the total liabilities
MIST's quick ratio has plunged by 74% YoY but it is up by 8% from the previous quarter
The current ratio has plunged by 74% YoY but it has grown by 6% from the previous quarter
The company's equity has shrunk by 190% QoQ and by 155% YoY
MIST's debt to equity has surged by 65% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.